Aurobindo shows not all healthcare has been healthy during the pandemic

Coronavirus 501 Earnings 647 Health Care 340 India 463 Quote Watch 417 U.S. 5149

Generic drug manufacturer Aurobindo reported a 2.5% dip in FQ4’21 (to March 31) revenues as a result of lower formulated drug sales in the U.S. That is partly “due to a reduction in hospital procedures on the back of COVID-19” though requests for sales rep visits to doctor surgeries in the U.S. “have improved, but it has not reached the pre-COVID level.” The firm’s supply chain activity already shows it anticipating the recovery, with total Indian exports linked to the firm up by 5.7% year over year in Q1’21. U.S. seaborne imports linked to the firm meanwhile jumped 34.4% year over year ...

Copyright © 2021 Panjiva Supply Chain Intelligence, a product offering from S&P Global Market Intelligence Inc. All rights reserved.